Smoking and Epstein–Barr virus infection in multiple sclerosis development

Anna Karin Hedström1,2,3, Jesse Huang2,3, Nicole Brenner4, Julia Butt4, Jan Hillert2,3, Tim Waterboer4, Ingrid Kockum2,3, Tomas Olsson2,3,5 & Lars Alfredsson1,2,5

It is unclear whether smoking interacts with different aspects of Epstein–Barr virus (EBV) infection with regard to multiple sclerosis (MS) risk. We aimed to investigate whether smoking acts synergistically with elevated EBNA-1 antibody levels or infectious mononucleosis (IM) history regarding MS risk. Two Swedish population-based case–control studies were used (6,340 cases and 6,219 matched controls). Subjects with different smoking, EBNA-1 and IM status were compared regarding MS risk, by calculating odds ratios (OR) with 95% confidence intervals (CI) employing logistic regression. Potential interaction on the additive scale was evaluated by calculating the attributable proportion due to interaction (AP). Current and past smokers had higher EBNA-1 antibody levels than never smokers (p < 0.0001). There was an additive interaction between current smoking and high EBNA-1 antibody levels (AP 0.3, 95% CI 0.2–0.4), but not between past smoking and high EBNA-1 antibody levels (AP 0.01, 95% CI −0.1 to 0.1), with regard to MS risk. An interaction also occurred between current smoking and IM history (AP 0.2, 95% CI 0.004–0.4), but not between past smoking and IM history (AP −0.06, 95% CI −0.4 to 0.3). Current smoking increases EBNA-1 antibody levels and acts synergistically with both aspects of EBV infection to increase MS risk, indicating that there is at least one pathway to disease in which both risk factors are involved.

Multiple sclerosis (MS) is an inflammatory disease of the central nervous system with underlying genetic and environmental factors. Smoking, high levels of EBNA-1 Immunoglobulin G (IgG), and infectious mononucleosis (IM) history have consistently been associated with increased MS risk1–3.

Previous studies on the interplay between smoking and aspects of EBV infection have used different study designs and statistical methods, and sample sizes have often been limited which may have contributed to conflicting results (Table 1). The first study observed a positive interaction on the multiplicative scale between smoking and elevated EBNA-1 IgG levels with regard to MS risk4. Smoking was only observed to increase MS risk among subjects with high EBNA-1 IgG levels. These findings were not replicated in other studies5–7. A recent study showed a trend towards a negative interaction among young adults and a trend towards a positive interaction among older subjects, as defined by age at EBV assessment, suggesting age may influence the interaction between smoking and EBNA-1 IgG levels8.

Results from previous studies on a possible interaction between smoking and IM history have also been conflicting. Two studies found no interaction between smoking and IM history6,7, whereas a recent study reported a negative interaction on the multiplicative scale regarding MS risk8. Using two Swedish population-based case–control studies comprising 6,340 cases and 6,219 controls, we aimed to investigate the interplay between smoking and different aspects of EBV infection [elevated EBNA-1 IgG levels and infectious mononucleosis (IM) history] with regard to MS risk.

1Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. 2Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. 3Center for Molecular Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden. 4German Cancer Research Center (DKFZ), Heidelberg, Germany. 5These authors contributed equally: Tomas Olsson and Lars Alfredsson. *email: anna.hedstrom@ki.se
### Table 1. Studies on the potential interaction between smoking and measures of EBV.

| Reference | No. of cases/controls | Exposure definitions | Interaction | Study design, comments |
|-----------|----------------------|----------------------|-------------|------------------------|
| 4         | 442/865              | EBNA1 antibody levels Ever/never smoking at diagnosis | Positive multiplicative interaction (p value 0.0001) Additive interaction not tested | Pooled analyses from two case–control studies (Sweden and Tasmania) and one prospective study (United States) |
| 5         | 662/848              | EBNA1 antibody levels Ever/never smoking before disease onset | No multiplicative interaction Additive interaction, AP – 0.04 (~ 0.4 to 0.3) | Swedish population-based case–control study |
| 6         | 1,237/488            | EBNA1 antibody levels Ever/never smoking before disease onset | No multiplicative interaction Additive interaction not tested | Case–control study (Accelerated Cure Project for Multiple Sclerosis) |
| 7         | 206/217              | EBNA1 antibody levels Ever/never smoking before disease onset | No additive or multiplicative interactions | Australian incident case–control study |
| 8         | 192/384              | EBNA1 antibody levels Cotinine levels < 10 or > 10 ng/ml at | No multiplicative interaction Additive interaction, AP 0.2 (~ 0.2 to 0.6) | Swedish nested case–control study |
| 9         | 1904/3,694           | IM history Ever/never smoking before disease onset | No multiplicative interaction Additive interaction not tested | Case–control study (Accelerated Cure Project for Multiple Sclerosis) |

### Methods

The present report is based on two Swedish population-based case–control studies; Epidemiological Investigation of Multiple Sclerosis (EIMS) and Genes and Environment in Multiple Sclerosis (GEMS). The study base comprised the general population aged 16–70 years.

EIMS recruited incident cases of MS from neurology clinics throughout the country between April 2005 and June 2015. For each case included in the study, two controls were randomly selected from the national population register, frequency matched for the case’s age in 5-year age strata, sex, and residential area.

GEMS identified prevalent cases from the Swedish National MS-registry. Controls, matched for age, sex, and residential area at the time of disease onset, were recruited in the same manner as in EIMS. The study participants were recruited between November 2009 and November 2011. All cases in both studies fulfilled the McDonald criteria. The studies were approved by the Regional Ethical Review Board at Karolinska Institutet and have therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All participants provided informed consent.

### Data collection and exposure information.

All participants in both studies answered a detailed questionnaire regarding environmental exposures and lifestyle factors. Questionnaires were completed by 2,880 cases and 6,122 controls in EIMS, and by 6,136 cases and 5,408 controls in GEMS. The response rate was 93% for cases and 73% for controls in EIMS, and 82% for cases and 66% for controls in GEMS. All participants were asked to provide a blood sample and those who did not were excluded. Blood samples were available for 2,021 cases and 2,449 controls in EIMS and for 4,319 cases and 3,770 controls in GEMS. The present study is thus based on 6,340 cases and 6,219 matched controls.

### Genotyping and measurement of EBNA-1 IgG levels.

HLA-DRB1 and HLA-A alleles were determined at four-digit resolution. Genotyping was performed on the MS replication chip which is based on an Illumina exome chip to which approximately 90,000 custom markers were added with extra high density in the HLA region and HLA was then imputed with HLA*IMP:0212.

Multiplex serology was used for detection of IgG antibodies against the EBNA-1 peptide segment (aa 385–420) which has been identified as the primary EBNA-1 fragment associated with MS risk. Dual-laser flow-based detection was used to quantify the antibodies as units of median fluorescence intensity.

### Definitions of exposures.

Participants were asked to provide information about current and previous smoking, including duration of smoking and average number of cigarettes smoked per day. The year of disease onset in the cases was defined as the index year and the corresponding controls were given the same index year. Smoking habits were only considered before the index year. Those who had smoked during the index year were defined as current smokers, those who had stopped smoking prior to the index year were defined as past smokers, and those who had never smoked before or during the index year were defined as never smokers.

EBNA-1 IgG levels were dichotomized based on the median seroreactivity among controls (5,620 MFI) defined at four-digit resolution. Genotyping was performed on the MS replication chip which is based on an Illumina exome chip to which approximately 90,000 custom markers were added with extra high density in the HLA region and HLA was then imputed with HLA*IMP:0212.

### Statistical analysis.

Subjects categorized based on smoking status, EBNA-1 IgG levels and IM history were compared with regard to MS risk, by calculating odds ratios (OR) with 95% confidence intervals (CI) using logistic regression models.
Table 2. OR with 95% CI of developing MS among subjects categorized by EBNA1 status and smoking. AP with 95% CI between high EBNA1 IgG and smoking. *Number of exposed cases and controls. aAdjusted for age, sex, residential area, study, and ancestry. bAdjusted for age, sex, residential area, study, ancestry, infectious mononucleosis, adolescent body mass index, DRB1*1501, DRB1*0301, DRB1*1303, DRB1*0801, A*0201, B*4402, B*3801, B*5501, DQA1*0101, DQB1*0302, DQB1*0301, homozygote correction for DRB1*1501, DRB1*0301, and A*0201.

| EBNA-1 IgG | Smoking | ca/coa | OR (95% CI)a | OR (95% CI)b | AP (95% CI) |
|-----------|---------|--------|--------------|--------------|------------|
| Low       | Never   | 689/1656 | 1.0 (reference) | 1.0 (reference) |            |
| Low       | Ever    | 808/1389 | 1.4 (1.3 to 1.6) | 1.5 (1.3 to 1.7) |            |
| High      | Never   | 2085/1642 | 3.1 (2.7 to 3.4) | 2.7 (2.4 to 3.0) |            |
| High      | Ever    | 2758/1532 | 4.4 (3.9 to 4.9) | 3.8 (3.4 to 4.3) | 0.2 (0.1 to 0.3) |
| Low       | Never   | 689/1656 | 1.0 (reference) | 1.0 (reference) |            |
| Low       | Current | 505/814  | 1.5 (1.3 to 1.7) | 1.6 (1.4 to 1.8) |            |
| High      | Never   | 2085/1642 | 3.1 (2.7 to 3.4) | 2.7 (2.4 to 3.0) |            |
| High      | Current | 1820/887  | 4.9 (4.4 to 5.5) | 4.4 (3.9 to 5.0) | 0.3 (0.2 to 0.4) |
| Low       | Never   | 689/1656 | 1.0 (reference) | 1.0 (reference) |            |
| Low       | Past    | 303/575  | 1.3 (1.1 to 1.5) | 1.4 (1.1 to 1.6) |            |
| High      | Never   | 2085/1642 | 3.1 (2.7 to 3.4) | 2.7 (2.4 to 3.0) |            |
| High      | Past    | 938/645  | 3.6 (3.1 to 4.1) | 3.1 (2.7 to 3.6) | 0.01 (~0.1–0.1) |

Sufficient-cause interaction is present when two risk factors are involved in the same pathway towards disease. Rothman has shown that independent risk factors adhere on the additive model and that interaction results in departure from additivity of disease rates. Since the logistic regression model is inherently multiplicative, presence of an interaction term implies departure from multiplicativity, which has no direct relevance for the issue of whether or not sufficient-cause interaction is present. Interaction should thus preferably be assessed on the additive scale.

Interaction on the additive scale between smoking and aspects of EBV infection (EBNA1-status and IM respectively) was assessed by calculating the attributable proportion due to interaction (AP). In order to estimate the influence of age at EBV assessment on the potential interaction between smoking and EBNA1-status, we performed the analyses stratified by age at EBV assessment, using the same cut-off as in a previous study (<50 years or ≥50 years). Since interactions have been reported between the main genetic risk factor for MS, the DRB1*15:01 allele, and both smoking, high EBNA1 IgG and past IM, we also stratified the analyses by DRB1*15:01 status.

All analyses were adjusted for age, sex, residential area, study, ancestry, adolescent body mass index (BMI), DRB1*03:01, DRB1*13:03, DRB1*08:01, A*02:01, B*44:02, B*38:01, B*55:01, DQA1*01:01, DQB1*03:02, DQB1*03:01, homozygote correction for DRB1*15:01, DRB1*03:01, and A*02:01. Inadequate correction was made for DRB1*15:01 status.

We additionally adjusted the analyses for passive smoking (yes or no), sun exposure habits (high or low), education (no post-secondary education, post-secondary education without university degree, or university degree), and socioeconomic index (employees at higher levels, employees at lower levels, and others), but these variables only had minor influence on the results and were not kept in the final analyses. These definitions have been described in previous publications based on the same studies.

The proportion of missing data regarding IM history was 12% among cases and 16% among controls. We therefore conducted supplementary analyses after imputing missing data using the multiple imputation chained equation procedure. We also conducted a sensitivity analysis in which smoking habits were considered 2 years prior to the index year. All analyses were conducted using Statistical Analysis System (SAS) version 9.4.

Results
Our analyses regarding the interplay between smoking and different aspects of EBV infection with regard to MS risk included 6,340 MS cases and 6,219 controls. Characteristics of cases and controls, overall and by smoking status, are presented in online resource 1. Ever smoking was associated with increased MS risk regardless of EBNA1 status (OR 1.4, 95% CI 1.3–1.6 among subjects with high EBNA1 IgG and OR 1.4, 95% CI 1.2–1.7 among those with low EBNA1 IgG). However, ever smokers had higher EBNA1 IgG levels than never smokers, both among cases and controls (p values for significance between groups were <0.0001).

There was an interaction on the additive scale between current smoking and high EBNA1 IgG levels (AP 0.3, 95% CI 0.2–0.4), but not between past smoking and high EBNA1 IgG levels (AP 0.01, 95% CI –0.1 to 0.1) (Table 2). The interaction between current smoking and high EBNA1 IgG levels remained similar in both groups when the analysis was stratified by age at EBV assessment (Table 3) and by DRB1*15:01 status (Table 4).

A significant additive interaction also occurred between current smoking and IM history (Table 5).
All main findings remained significant when the studies were analyzed separately (data not shown). Our results remained almost identical after carrying out the analyses on the multiple imputed data (data not shown).

Table 3. OR with 95% CI of developing MS among subjects categorized by EBNA1 status and smoking, stratified by age at EBV assessment. AP with 95% CI between high EBNA1 IgG and smoking. *Number of exposed cases and controls

| EBNA-1 IgG | Smoking | DRB1*15:01 positive subjects | DRB1*15:01 negative subjects |
|------------|---------|-----------------------------|-------------------------------|
|            | OR (95% CI) | OR (95% CI) | OR (95% CI) | OR (95% CI) |
| Low        | Never    | 387/1045 | 1.0 (reference) | 302/611 | 1.0 (reference) |
| Low        | Current  | 233/387 | 1.3 (1.1-1.9)  | 282/427 | 1.3 (1.1-1.6)  |
| High       | Never    | 1227/1005 | 3.3 (2.9-3.8) | 858/637 | 2.7 (2.3-3.2)  |
| High       | Current  | 836/426  | 4.6 (3.9-5.5)  | 984/461  | 4.3 (3.6-5.1)  |

Table 4. OR with 95% CI of developing MS among subjects categorized by EBNA1 status and smoking, stratified by DRB1*15:01 status. AP with 95% CI between high EBNA1 IgG and smoking. *Number of exposed cases and controls

| IM history | Smoking | OR (95% CI) | OR (95% CI) | AP (95% CI) |
|------------|---------|-------------|-------------|-------------|
| No         | Never   | 1989/2625 | 1.0 (reference) | 1.0 (reference) |
| No         | Ever    | 2518/2304 | 1.4 (1.3 to 1.6) | 1.5 (1.3 to 1.6) |
| Yes        | Never   | 380/289  | 1.8 (1.5 to 2.1) | 1.7 (1.5 to 2.1) |
| Yes        | Ever    | 429/213  | 2.7 (2.3 to 3.2) | 2.5 (2.0 to 3.0) | 0.1 (−0.1 to 0.3) |
| No         | Never   | 1989/2625 | 1.0 (reference) | 1.0 (reference) |
| No         | Current | 1624/1371 | 1.5 (1.4 to 1.7) | 1.6 (1.4 to 1.7) |
| Yes        | Never   | 380/289  | 1.8 (1.5 to 2.1) | 1.8 (1.5 to 2.1) |
| Yes        | Current | 269/110  | 3.2 (2.6 to 4.1) | 3.0 (2.3 to 3.8) | 0.2 (0.004 to 0.4) |
| No         | Never   | 1989/2625 | 1.0 (reference) | 1.0 (reference) |
| No         | Past    | 894/933  | 1.3 (1.2 to 1.5) | 1.3 (1.2 to 1.5) |
| Yes        | Never   | 380/289  | 1.8 (1.5 to 2.1) | 1.7 (1.5 to 2.1) |
| Yes        | Past    | 160/103  | 2.1 (1.7 to 2.8) | 1.9 (1.5 to 2.6) | −0.06 (−0.4 to 0.3) |
MS risk. Whether enhanced reactivity to other unique EBNA-1 epitopes interact with smoking to increase MS segment has been identified as the primary EBNA-1 fragment for which antibody response is associated with smoking and EBV, which is affected by genetic constitution and probably also by other environmental factors.

departure from multiplicativity, which has no direct relevance for the issue of whether or not sufficient-cause interactions only occur between current smoking and EBV infection, the likelihood of a negative finding increases if the past smokers are classified as ever smokers together with the current smokers, especially if the proportion of past smokers is large. The last study, performed in Sweden, used cotinine levels as a measure of smoking6. However, cotinine levels are also high in users of smokeless tobacco and nicotine, which when considered in isolation of the products of combustion, has been associated with reduced MS risk. In Sweden, where the use of smokeless tobacco is a common habit, cotinine levels may not be a good proxy for smoking. Some studies, including the largest one6, only assessed multiplicative interaction whereas additive interaction was not considered. Since the logistic regression model is inherently multiplicative, presence of an interaction term implies departure from multiplicativity, which has no direct relevance for the issue of whether or not sufficient-cause interaction is present7. Taken together, this may explain previous contradictory results.

After primary EBV infection, the virus remains in a latent phase in resting memory B cells. The virus may be reactivated during periods of environmental stress, whereby the EBV antibodies against viral antigens become elevated. Smokers have higher levels of anti-EBV antibodies26,27 and higher EBV viral load28,29 compared to non-smokers, and several studies indicate that smoking may trigger EBV reactivation30,31. Smoking alters the development and function of both innate and adaptive immune cells, and leads to pro-inflammatory responses and dysfunction of immune cells32. Memory B-cells play an important role in MS pathogenesis since they are reservoirs for EBV latency. They are antigen-presenting cells, which may activate autoreactive T-cells against CNS antigens. Several MS-associated risk alleles responsible for the regulation of B-cell functions have been identified33. Smoking increases the frequency of memory B cells and lowers regulatory B cell numbers32,34. Smoking also has anti-estrogen effect which may alter survival and activation of autoreactive B cells and skew the immune system toward autoimmunity35.

The components in cigarette smoke also affect the immune system barrier function and may promote the migration of autoreactive immune cells into the CNS36. Furthermore, epigenetic alterations are induced by smoking, including extensive genome-wide changes in DNA methylation37,38. Smoking-associated DNA methylation and changes in gene expression among immune cell types have been identified and may contribute to EBV reactivation39.

Both HLA and non-HLA genes are involved in controlling EBV infection40,41, and both high EBNA-1 IgG levels and past IM interact with carriage of DRB1*15:01 and absence of HLA-A*02:0142. The DRB1*15:01 allele affects the humoral response to EBV and genetic differences in the class I locus have been shown to influence both the outcome of primary EBV infection and the viral persistence42,43. Smoking has been shown to interact with the same MS-associated HLA genes40. Altogether, these findings point towards a complex interaction between smoking and EBV, which is affected by genetic constitution and probably also by other environmental factors.

Individuals with MS often show enhanced response to several epitopes in EBNA-1. In the present study, we defined high EBNA-1 IgG levels as increased reactivity against peptides that spanned aa 385–420 since this is more informative from a public health perspective. Further, the sufficient-cause concept that was developed by Rothman and later expanded by Vanderweele has improved the understanding between disease causation and interaction, in that presence of interaction between two causal factors on the additive scale implies that there exists a pathway towards disease where the presence of both risk factors are needed.

Both EIMS and GEMS were designed as case–control studies and information on exposures and lifestyle factors was collected retrospectively. There could be a potential recall bias in this design and we made great efforts to obtain exposure information from cases and controls in an identical way. The questionnaire comprised a large number of questions regarding many environmental and lifestyle habits, and no section in the questionnaire was given main focus.

In both studies, selection bias was minimized by the population-based design. The health care system in Sweden provides equal free of charge access to medical services for all citizens, and MS cases are referred to neurological units, making them eligible to be part of the studies. Although the relatively high proportion of non-responders among the controls may introduce selection bias, it is probably modest since the prevalence of life style factors, such as smoking and alcohol consumption, among the controls was consistent with that of the general population in similar ages44. Blood samples for genetic and serologic analyses were not available for a substantial proportion of cases and controls, which were excluded from the study. Among both cases and controls, smokers were more prone to provide blood. However, the OR of MS associated with smoking was the same among those who did and did not donate blood. There is no reason to believe that DRB1*15:01 status or EBNA-1 IgG levels would differ...
between those who donated blood and those who did not. We thus consider it unlikely that our findings would be affected by bias to a large extent.

In conclusion, current smoking increases EBNA-1 IgG levels and acts synergistically with both aspects of EBV infection to increase MS risk.

Data availability
Anonymized data will be shared by request from any qualified investigator that wants to analyze questions that are related to the published article.

Received: 18 November 2019; Accepted: 29 May 2020
Published online: 03 July 2020

References
1. Hedström, A. K., Hillert, J., Olsson, T. & Alfredsson, L. Smoking and multiple sclerosis susceptibility. *Eur. J. Epidemiol.* **28**, 867–874 (2013).
2. Levin, I. L. et al. Primary infection with the Epstein–Barr virus and risk of multiple sclerosis. *Ann. Neurol.* **67**, 824–830 (2010).
3. Handel, A. E., et al. An updated meta-analysis of risk of multiple sclerosis following infectious mononucleosis. *PloS One* **5**, e12496 (2010).
4. Simon, K. C. et al. Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. *Neurology* **74**, 1365–1371 (2010).
5. Sundqvist, E. et al. Lack of replication of interaction between EBNA1 IgG and smoking in risk for multiple sclerosis. *Neurology* **79**, 1363–1368 (2012).
6. Simon, K. C., Schmidt, H., Lound, S. & Ascherio, A. Risk factors for multiple sclerosis, neuromyelitis optica and transverse myelitis. *Mult. Scler.* **21**, 703–709 (2015).
7. van der Mei, I.
8. Salzer, J., Stenlund, H. & Sundström, P. The interaction between smoking and Epstein–Barr virus as multiple sclerosis risk factors.
9. Bjornevik, K.
10. Sundqvist, E.
11. Rothman, K. J.
12. Handel, A. E., et al. Multiple sclerosis genomic map implicates peripheral immune cells and migrolgia in susceptibility. *Science*, **365**, eaav7188 (2019).
13. Dithhey, A. et al. Multi-population classical HLA type imputation. *PLoS Comput. Biol.* **9**, e1002877 (2013).
14. Waterboer, T. et al. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. *Clin. Chem.* **51**, 1845–1853 (2005).
15. Tengvall, K. et al. Molecular mimicry between ancanotin 2 and Epstein–Barr virus nuclear antigen 1 associates with multiple sclerosis risk. *Proc. Natl. Acad. Sci. U.S.A.* **116**, 16955–16960 (2019).
16. Sundqvist, E. et al. Epstein–Barr virus and multiple sclerosis: Interactions with HLA. *Genes Immun.* **13**, 14–20 (2012).
17. Rothman, K. J. et al. (eds) *Modern Epidemiology* 3rd edn. (Lippincott Wolliams & Wilkins, Philadelphia, 2008).
18. Ahlbom, A. & Alfredsson, L. Interaction: A word with two meanings creates confusion. *Eur. J. Epidemiol.* **20**, 583–584 (2005).
19. VanderWeele, T. J. Sufficient cause interactions and statistical interactions. *Epidemiology* **20**, 6–13 (2009).
20. Moutsianas, L. et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. *Nat. Genet.* **47**, 1107–1113 (2015).
21. Hedström, A. K. Smoking and its interaction with genetics in MS etiology. *Mult. Scler.* **25**, 180–186 (2019).
22. Hedström, A. K. et al. High levels of Epstein–Barr Virus nuclear antigen-1-specific antibodies and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk. *Front. Neurol.* **10**, 1368 (2019).
23. Hedström, A. K., et al. The influence of human leukocyte antigen-DRB1*1501 and its interaction with smoking in MS development is dependent on DQA1*01:01 status. *Mult. Scler.* **25**, 222–240 (2019).
24. Enders, C. K., Mustler, S. A. & Keller, B. T. Multilevel multiple imputation: A review and evaluation of joint modeling and chained equations imputation. *Psychol. Methods* **21**, 222–240 (2016).
25. He, Y. Q. et al. The relationship between environmental factors and the profile of Epstein–Barr virus antibodies in the lytic and latent infection periods in healthy populations from endemic and non-endemic nasopharyngeal carcinoma areas in China. *Ebio-Medicine* **30**, 184–191 (2018).
26. Nielsen, T. R., Pedersen, M., Rostgaard, K., Frisch, M. & Hjalgrim, H. Correlations between Epstein–Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. *Mult. Scler.* **13**, 420–423 (2007).
27. Chan, K. C. A., Chu, S. W. I. & Lo, Y. M. D. Ambient temperature and screening for nasopharyngeal cancer. *N. Engl. J. Med.* **378**, 962–963 (2018).
28. He, Y. Q., Liao, X. Y. & Xue, W. Q. Association between environmental factors and oral Epstein–Barr virus DNA loads: A multicenter cross-sectional study in China. *J. Infect. Dis.* **219**, 400–409 (2019).
29. Xu, F. H. et al. An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein–Barr virus activation. *J. Natl. Cancer Inst.* **104**, 1396–1410 (2012).
30. Hu, T. et al. Smoking can increase nasopharyngeal carcinoma risk by repeatedly reactivating Epstein–Barr virus: An analysis of a prospective study in southern China. *Cancer Med.* **8**, 2561–2571 (2019).
31. Qu, F., Liang, C. L. & Liu, H. Impacts of cigarette smoke on immune responsiveness: Up and down or upside down? *Oncoarget.* **8**, 268–284 (2017).
32. Smets, I., Fiddes, B. & Garcia-Perez, J. E. Multiple sclerosis risk variants alter expression of co-stimulatory genes in B cells. *Brain* **141**, 786–796 (2018).
33. Li, G., Wulan, H. & Song, Z. Regulatory B cells function is suppressed by smoking and obesity in *H. pylori*-infected subjects and is correlated with elevated risk of gastric cancer. *PloS One* **10**, e0134591 (2015).
34. Grimaldi, C. M., Cleary, J., Dagtas, A. S., Moussai, D. & Diamond, B. Estrogen alters thresholds for B cell apoptosis and activation. *J. Clin. Investig.* **109**, 1625–1633 (2002).
35. Prasad, S. et al. Impact of cigarette smoke extract and hyperglycemic conditions on blood–brain barrier endothelial cells. *Fluids Barriers CNS* **12**, 18 (2015).
37. Gao, X., Jia, M. & Zhang, Y. DNA methylation changes of whole blood cells in response to active smoking exposure in adults: A systematic review of DNA methylation studies. Clin. Epigenet. 7, 113 (2015).
38. Joehanes, R. et al. Epigenetic signatures of cigarette smoking. Circ. Cardiovase. Genet. 9, 436–447 (2016).
39. Su, D. et al. Distinct epigenetic effects of tobacco smoking in whole blood and among leukocyte subtypes. PLoS ONE 11, e0166486 (2016).
40. Kreft, K. L. et al. Elevated EBNA-1 IgG in MS is associated with genetic MS risk variants. Neurol. Neuroimmunol. Neuroinflamm. 4, e406 (2017).
41. Zhou, Y. et al. Genetic loci for Epstein–Barr virus nuclear antigen-1 are associated with risk of multiple sclerosis. Mult. Scler. 22, 1655–1664 (2016).
42. McAulay, K. A. et al. HLA class I polymorphisms are associated with development of infectious mononucleosis upon primary EBV infection. J. Clin. Investig. 117, 3042–3048 (2007).
43. Agostini, S. et al. HLA alleles modulate EBV viral load in multiple sclerosis. J. Transl. Med. 16, 80 (2018).
44. Internet based information. https://www.scb.se. Accessed 16 Apr 2019.

Acknowledgements
The study was supported by grants from the Swedish Medical Research Council; from the Swedish Research Council for Health, Working Life and Welfare, Horizon2020 MultipleMS, Margareta af Ugglas foundation, the Swedish Brain Foundation, and the Swedish Society for Medical Research. Open access funding provided by Karolinska Institute.

Author contributions
A.K.H.: study concept and design, statistical analysis, drafting of the manuscript. J.H., J.B., N.B., T.W., I.K.: data extraction, interpretation of data, critical revision of manuscript. J.H., T.O., L.A.: study concept and design, interpretation of data, critical revision of manuscript. All authors approved the final version of the manuscript to be published.

Competing interests
Hedström, Huang, Brenner, Butt, and Waterboer report no disclosures. Kockum received speaker’s fees from Biogen and Novartis and speaker’s fees from Biogen, Merck-Serono, Bayer-Schering, Teva and Sanofi-Aventis. He has served as principal investigator for projects sponsored by, or received unrestricted research support from, Biogen, Merck-Serono, TEVA, Novartis and Bayer-Schering. TO served on scientific advisory boards and received speaker honoraria Novartis, Merck-Serono, Biogen Idec, TEVA and Genzyme; served as Co-editor of Current Opinion in Immunology; received from Novartis and Biogen; and receives research support from Novartis, Genzyme, Biogen Idec, the Swedish Research Council (07488), EU fp7 Neurinox, and CombiMS, and the Swedish Brain Foundation. Alfredsson received research support from the Swedish Medical Research Council (Dnr 2016-02349), the Swedish Council for Health, Working Life and Welfare (Dnr 2015-00195) and the Swedish Brain Foundation; has received speaker honoraria from Biogen Idec and TEVA.

Additional information
Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-67883-w.

Correspondence and requests for materials should be addressed to A.K.H.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2020